S.Korea's Qurient, US National Cancer Institute to develop anti-cancer drug

Both plan to evaluate the efficacy of the anti-cancer new drug candidate Q901 in treating small-cell lung cancer

S.Korea's Qurient, US National Cancer Institute to develop anti-cancer drug
Jeong Min Nam 1
2023-08-14 16:28:10 peux@hankyung.com
Bio & Pharma

South Korea's Qurient Co. announced on Monday that it signed a research and development agreement with the US government agency National Cancer Institute (NCI) regarding the investigational anti-cancer compound "Q901."

Under this agreement, Qurient and NCI will jointly evaluate the efficacy of Q901 in synergy with standard treatment regimens for small cell lung cancer (SCLC).

Q901 inhibits CDK7, a key factor in regulating the cell division cycle. It is a first-in-class anti-cancer compound candidate that induces cell cycle regulation, DNA damage repair inhibition and transcriptional control mechanisms. Q901 is currently undergoing Phase 1 and Phase 2 clinical trials in the United States and South Korea.

According to preliminary research by NCI, transcriptional regulation through the inhibition of CDK7 has shown significant anti-cancer effects in SCLC. Q901 has also demonstrated high efficacy for SCLC in preclinical experiments conducted by Qurient.

Write to Jeong Min Nam at peux@hankyung.com
#Qurient Therapeutics #National Cancer Institute #NCI #small cell lung cancer #SCLC #Q901 #CDK7 #transcriptional control

Gencurix joins US gov't Cancer Moonshot project

Gencurix joins US gov't Cancer Moonshot project

Gencurix's companion diagnostic tester Dropex  South Korean cancer molecular diagnostics company Gencurix Inc. announced on Monday that it joins US President Joe Biden's cancer-conquering project "Cancer Moonshot."The Cancer Moonshot is a policy by the Biden Administration aiming to reduce

Clinomics releases equipment that quickly finds lung cancer mutations

Clinomics releases equipment that quickly finds lung cancer mutations

Clinomics, a South Korean biotech company specializing in liquid biopsies, on Thursday said it developed equipment that can detect four types of lung cancer-causing epidermal growth factor receptor, or EGFR, gene mutations within three hours. The machine improves user convenience by aut

Novomics expands presence in Chinese cancer market

Novomics expands presence in Chinese cancer market

South Korean molecular diagnostics company Novomics Co. announced on Wednesday that it has signed a collaboration agreement with Chinese molecular diagnostics company TopGene.The purpose of the collaboration is to introduce Novomics' gastric cancer prognosis prediction test technology to the C

Prestige Biopharma participates in US gov’t Cancer Moonshot

Prestige Biopharma participates in US gov’t Cancer Moonshot

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, announced on Tuesday that it will participate in the US government's cancer eradication project "Cancer Moonshot."According to company sources, CancerX, a public-private collaboration est
(* comment hide *}